Skinvisible (SKVI) EBIT (2016 - 2025)
Skinvisible (SKVI) has disclosed EBIT for 16 consecutive years, with -$114169.0 as the latest value for Q4 2025.
- Quarterly EBIT rose 42.55% to -$114169.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$496315.0 through Dec 2025, up 15.82% year-over-year, with the annual reading at -$496315.0 for FY2025, 15.82% up from the prior year.
- EBIT hit -$114169.0 in Q4 2025 for Skinvisible, down from -$106057.0 in the prior quarter.
- In the past five years, EBIT ranged from a high of $159520.0 in Q2 2021 to a low of -$198743.0 in Q4 2024.
- Historically, EBIT has averaged -$81331.6 across 5 years, with a median of -$115942.5 in 2022.
- Biggest five-year swings in EBIT: soared 1813.37% in 2021 and later tumbled 1519.34% in 2022.
- Year by year, EBIT stood at $147540.0 in 2021, then tumbled by 179.79% to -$117716.0 in 2022, then decreased by 15.99% to -$136538.0 in 2023, then tumbled by 45.56% to -$198743.0 in 2024, then surged by 42.55% to -$114169.0 in 2025.
- Business Quant data shows EBIT for SKVI at -$114169.0 in Q4 2025, -$106057.0 in Q3 2025, and -$136237.0 in Q2 2025.